[Changes of control of disorders of calcium and phosphorus metabolism in Lithuanian hemodialysis centers 1996-2003].
The aim of the study was to evaluate the changes of the rate of disorders of calcium and phosphorus metabolism and their control in patients on hemodialysis (HD) in Lithuania in 1996-2003. Every December during this period we visited all HD centers of Lithuania and collected data on calcium-phosphorus metabolism in HD patients. 51.8% of HD patients in 1999 and 44.6% in 2003 had hyperphosphatemia (>1.8 mmol/l) (p<0.05). The mean phosphate concentration was 1.82+/-0.56 mmol/l in 2003 (p<0.05, comparing with 1.95+/-0.72 mmol/l in 1999 and 1.9+/-0.72 mmol/l in 2001). 7.1% of HD patients had hypocalcemia in 2003 and 7.8% hypercalcemia. Serum parathyroid hormone level was investigated only in 27.3% of HD patients in 1999 and 84.8% in 2003 (p<0.05). Use of alfacalcidol significantly decreased from 77.5% in 1998 to 29.4% in 2003, when the evaluation of serum parathyroid hormone increased (r=-0.911, p=0.03). Serum parathyroid hormone level was not analyzed for 59.8% of patients who used alfacalcidol and 59.4% of them had hyperphosphatemia in 1999 (6.3% and 32.9% in 2003, respectively; p<0.05). 10.7% of these patients had hypercalcemia in 2003. In summary, the correction of disorders of calcium and phosphorus metabolism in HD patients was insufficient but ameliorative. Monitoring of serum parathyroid hormone increased significantly during 1997-2003. The percentage of the precarious use of alfacalcidol decreased significantly when the evaluation of serum parathyroid hormone level became regular.
Ziginskiene
Edita
E
Clinic of Nephrology, Kaunas University of Medicine Hospital, Eiveniu 2, 50009 Kaunas, Lithuania. nefrolog@kmu.lt
Kuzminskis
Vytautas
V
Bumblyte
Inga Arūne
IA
Kardauskaite
Zydrūne
Z
Uogintaite
Jurgita
J
D002118:Calcium / Q000097:blood; D002128:Calcium Metabolism Disorders / Q000628:therapy*; D005919:Glomerular Filtration Rate; D006801:Humans; D006887:Hydroxycholecalciferols / Q000008:administration & dosage / Q000627:therapeutic use*; D006934:Hypercalcemia / Q000628:therapy; D006962:Hyperparathyroidism, Secondary / Q000188:drug therapy / Q000503:physiopathology; D006996:Hypocalcemia / Q000628:therapy; D010281:Parathyroid Hormone / Q000097:blood*; D010710:Phosphates / Q000097:blood; D010760:Phosphorus Metabolism Disorders / Q000628:therapy*; D006435:Renal Dialysis
D006887:Hydroxycholecalciferols; D010281:Parathyroid Hormone; D010710:Phosphates; D002118:Calcium; C008088:alfacalcidol